Company intelligence / Profile preview

Camp Corporation

Cambridge, Massachusetts, United Statesnytimes.com ↗

Ownership: Private
Development stage: Commercial

Overview

CAMP4’s lead candidate CMP-CPS-001 for urea cycle disorders is in a Phase 1 clinical trial. The company has reported favorable safety results from the single ascending dose portion and completed dosing in two multiple ascending dose cohorts. Additional programs are advancing preclinically.

Therapeutic areas: Metabolic DisordersNeurology
Modalities: Antisense oligonucleotideRNA therapy
Industry: Biotech

Partnerships

Not specifically disclosed; strategic guidance from industry veterans on board

Beyond the preview

Go deeper on Camp Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Camp Corporation.

Explore the full profile